DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Amphetamineis the generic ingredient in twenty-six branded drugs marketed by Neos Theraps Inc, Tris Pharma Inc, Neos Theraps, Teva, Takeda Pharms Usa, Actavis Elizabeth, Ani Pharms Inc, Elite Labs Inc, Impax Labs, Mylan, Nesher Pharms, Par Pharm Inc, Rhodes Pharms, Specgx Llc, Sun Pharm Industries, Barr Labs Inc, Teva Womens, Alvogen, Aurolife Pharma Llc, Barr, Epic Pharma Llc, Nuvo Pharm, Sandoz, Teva Pharms, Uspharma, Ucb Inc, Arbor Pharms Llc, Alkem Labs Ltd, Amneal Pharms, Bionpharma Inc, Cerovene Inc, Granules Pharms, Havix, Lannett, Mayne Pharma, Novast Labs, and Prinston Inc, and is included in fifty NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Amphetamine has twenty-three patent family members in fourteen countries.
There are fifty-five drug master file entries for amphetamine. Three suppliers are listed for this compound.
Summary for amphetamine
|Drug Master File Entries:||55|
|Suppliers / Packagers:||3|
|Bulk Api Vendors:||29|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for amphetamine|
|Drug Sales Revenues:||Drug sales revenues for amphetamine|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for amphetamine|
|What excipients (inactive ingredients) are in amphetamine?||amphetamine excipients list|
|DailyMed Link:||amphetamine at DailyMed|
Recent Clinical Trials for amphetamine
Identify potential brand extensions & 505(b)(2) entrants
|University of Alabama at Birmingham||Phase 4|
|San Francisco Department of Public Health||Phase 1|
|University of California, Los Angeles||Early Phase 1|
Pharmacology for amphetamine
|Drug Class||Central Nervous System Stimulant |
|Physiological Effect||Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for amphetamine
|Country||Patent Number||Estimated Expiration|
|South Korea||101495146||Start Trial|
|Russian Federation||2435569||Start Trial|
|European Patent Office||2018160||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.